Meet Dr. Henrik Zetterberg

Dr. Zetterberg  has developed new diagnostic tests for Alzheimer’s disease, as well as new preclinical models, and has shown that (i) amyloid pathology precedes tau pathology by around five years during the Alzheimer’s disease process in humans, (ii) altered amyloid homeostasis in the brain is evident already in pre-symptomatic stages of the disease, and (iii) the diagnostic usefulness of Alzheimer’s biomarkers decreases with age due to increased prevalence of preclinical Alzheimer neuropathology. 

Dr. Zetterberg has received numerous prizes, including the Erik K. Fernström Prize for Junior Scientists and the Inga Sandeborg Prize for Research on Alzheimer’s Disease. He is professor of neurochemistry and head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy, senior consultant in clinical chemistry at the Sahlgrenska University Hospital, guest professor of neurochemistry at University College London and a Wallenberg Academy Fellow. 

How Henrik Supports Optoceutics
Dr. Henrik Zetterberg is integral to Optoceutics for his unparalleled expertise in biomarker research, contributing to the analysis and interpretation of biomarkers in ongoing Alzheimer’s trials. 

Current or Past Scientific Advisory Boards:

Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, CogRx

Lectures Given in Symposia:

Sponsored by Fujirebio, Sponsored by Alzecure, Sponsored by Biogen.